NCT06431620View on ClinicalTrials.gov

Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Advanced/Metastatic Differentiated Thyroid Cancer

NARecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

December 31, 2026

Conditions
Recombinant Human Thyroid Stimulating Hormone
Interventions
DRUG

Recombinant Human Thyroid Stimulating Hormone

recombinant human thyrotropin (rhTSH) injection: 0.9mg/1.0mL/piece; intramuscular injection; once a day for two consecutive days.

Trial Locations (1)

210006

RECRUITING

The First Affiliated Hospital of Nanjing Medical Univerity, Nanjing

All Listed Sponsors
lead

Nanjing First Hospital, Nanjing Medical University

OTHER